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Abstract 
The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. 
The use of 8‑aminoquinolines is hampered by haemolytic side effects in glucose‑6‑phosphate dehydrogenase (G6PD) 
deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been 
developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recom‑
mended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in 
the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine 
G6PD testing. Two point‑of‑care (PoC) test formats for the measurement of G6PD activity are currently available: 
qualitative tests comparable to malaria RDT as well as biosensors that provide a quantitative reading. Qualitative G6PD 
PoC tests provide a binomial test result, are easy to use and some products are comparable in price to the widely used 
fluorescent spot test. Qualitative test results can accurately classify hemizygous males, heterozygous females, but may 
misclassify females with intermediate G6PD activity. Biosensors provide a more complex quantitative readout and are 
better suited to identify heterozygous females. While associated with higher costs per sample tested biosensors have 
the potential for broader use in other scenarios where knowledge of G6PD activity is relevant as well. The introduc‑
tion of routine G6PD testing is associated with additional costs on top of routine treatment that will vary by setting 
and will need to be assessed prior to test introduction. Reliable G6PD PoC tests have the potential to play an essential 
role in future malaria elimination programmes, however require an improved understanding on how to best integrate 
routine G6PD testing into different health settings.
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Introduction
Plasmodium vivax has long been considered a benign 
form of malaria, but this paradigm is changing. Vivax 
malaria can have a profound impact on health, particu-
larly in women and children from poorly resourced 
communities [1–3]. Successful control and ultimate 
elimination of P. vivax will require a radical cure, that 
combines a schizontocide to eliminate blood stages of 
the parasite and a hypnozoiticide to kill the liver stages. 
Primaquine, an 8-aminoquinoline (8-AQ), is the only 
widely available hypnozoiticide [4], although a new, 
slowly eliminated 8-aminoquinoline, tafenoquine is cur-
rently in Phase III clinical trials [5]. Although 8-amino-
quinolones are well tolerated by most individuals [6], 
this class of drugs can trigger haemolytic reactions in 
glucose-6-phosphate dehydrogenase (G6PD) deficient 
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recipients [7]. The risk of drug induced haemolysis in 
relatively small G6PD deficient subpopulations needs 
to be balanced with the risk of anaemia and other det-
rimental effects due to recurrent episodes of malaria in 
all vivax patients. Reliable, easy to perform point-of-care 
(PoC) tests provide a potential solution to this dilemma. 
If G6PD status can be assessed before commencing radi-
cal cure treatment, the threat of severe side effects from 
primaquine can be minimized in the at-risk population.
For several decades the research agenda for radical cure 
has been neglected and the demand for reliable, easy-to-
use G6PD tests has not been a priority. In the last dec-
ade malaria control and elimination programmes have 
gained considerable momentum, particularly in reduc-
ing the burden of P. falciparum. Increasingly the need 
for an improved management of P. vivax is recognized 
as a programmatic priority. Based on the experience in 
G6PD deficient African American soldiers, radical cure 
with primaquine was long considered safe; however, the 
potential risks in more severe variants of G6PD defi-
ciency can be considerable. In the most recent WHO 
treatment guidelines G6PD testing to guide radical cure 
is recommended whenever possible [8]. When testing is 
not possible the risks and benefits of primaquine treat-
ment must be weighed prior to drug administration. 
The administration of a single low dose of 0.25  mg/kg 
bw primaquine to kill P. falciparum gametocytes is con-
sidered unlikely to cause serious toxicity even in people 
with G6PD deficiency [8] and G6PD testing is not recom-
mended prior to the administration of a single low dose.
Since 2012 a series of workshops have been held by 
the Asia Pacific Malaria Elimination Network (APMEN) 
to discuss G6PD testing in the context of vivax malaria 
treatment in the Asia Pacific. The first workshop of this 
series was held in Incheon, South Korea in May 2012, 
where the research agenda for G6PD deficiency and the 
radical cure of P. vivax was reviewed, an update of avail-
able tests presented, and a target product profile for a 
point-of-care test for G6PD deficiency proposed [7]. The 
focus of the second workshop in October 2012 in Bang-
kok, Thailand was on use—case scenarios, updating the 
target product profile for point-of-care tests, and discuss-
ing criteria for their evaluation [9].
This article reports on the third workshop held at the 
Research Institute of Tropical Medicine (RITM), the 
Philippines, in February 2015, in a joint effort by the Asia 
Pacific Malaria Elimination Network (APMEN), RITM 
and PATH. Main objectives of the workshop were on the 
challenges and evidence gaps facing successful imple-
mentation of G6PD screening in the context of currently 
available and anticipated point-of-care tests for G6PD 
deficiency. The workshop included participants from 
Australia, Bangladesh, Cambodia, Indonesia, Malaysia, 
the Philippines, Thailand, UK, US and Vietnam, repre-
senting research institutions and country malaria control 
programmes. The discussion was timely in the context 
of the most recent recommendations emerging from the 
2014 WHO expert review group on G6PD deficiency 
[10], the resulting guidance from the March 2015 WHO 
Malaria Policy Advisory Committee and the recently 
published malaria treatment guidelines by the WHO [8].
Background
Glucose-6-phosphate dehydrogenase (G6PD) is an essen-
tial enzyme in the pentose phosphate pathway which is 
the sole source of energy for red blood cells (RBCs) and 
the only mechanism to maintain the cells redox potential 
[11]. In contrast to other human cells, RBCs do not have 
a nucleus and are hence reliant on the enzyme molecules 
provided during erythropoiesis. As a result the life expec-
tancy of healthy RBCs under normal circumstances is 
comparably short at around 120 days [12].
Intracellular enzyme activity in RBCs is a function of 
the initial abundance of the enzyme, enzyme half-life 
and the RBC half-life. G6PD deficiency (G6PDd) is the 
result of a structural defect of the G6PD enzyme and is 
one of the most common enzymopathies worldwide [13, 
14]. G6PD deficiencies vary from slightly reduced G6PD 
activities to extremely low G6PD activity even in young 
RBCs, while the absence of enzyme activity is not com-
patible with human life [15]. In 1989, the WHO G6PD 
working group proposed to categorize G6PDd into 
classes I–V [16] based on measured activity relative to 
normal G6PD activity (in percent). Defining an absolute 
quantitative 100 % G6PD activity is challenging due to its 
dependence on the population under consideration, the 
assay conditions and assay platform. Current definitions 
are population specific and based on the median G6PD 
Table 1 Calculating G6PD activity
The WHO has defined a total of five classes (I–V) of G6PD activity [16]:
 • Severe deficiency (<10 % activity, chronic, non‑spherocytic, haemolytic 
anaemia)
 • Severe deficiency (<10 % activity, intermittent haemolysis)
 • Mild deficiency (10–60 % activity, haemolysis with stressors only)
 • Normal enzyme variant (60–150 % activity, no clinical sequelae)
 • Increased enzyme activity (>150 % activity, no clinical sequelae)
100 % G6PD activity is based on the adjusted quantitative (iU/gHb or 
U/1012 RBC) median of all male samples from a defined sample set 
[9]. In a first step the median G6PD activity of samples from all male 
participants is calculated. Second, all samples with ≤10 % G6PD activity 
of the median are excluded. Third, the median is re‑calculated based on 
the remaining samples, the adjusted male median. The adjusted male 
median is defined as 100 % G6PD activity and all samples are grouped 
accordingly
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activity of all males excluding those that are hemizygous 
G6PD deficient (Table 1) [9].
The underlying G6PD gene is located on the X-chro-
mosome (Xq28), spans a total length of 18.5  kb and 
includes 13 exons and 12 introns [17]. More than 185 
G6PD mutations have been described to date [18] giving 
rise to hemizygous men as well as homozygous and het-
erozygous women, the latter possessing two distinct pop-
ulations of RBCs. In heterozygous females G6PD normal 
and G6PD deficient RBCs co-exist in varying propor-
tions determined by random X-chromosome inactivation 
(lyonization) [7].
Higher G6PD prevalence rates appear more com-
monly where higher rates of malaria transmission occur. 
Such trends may be directly related to protection against 
severe malaria conferred by some variants of G6PDd 
[19–22]. G6PDd affects approximately 400 million peo-
ple worldwide [23]. Manifestations can include neonatal 
jaundice, favism and haemolytic anemia but in the vast 
majority of G6PD deficient cases quality of life is not 
affected and G6PD deficient people may not even be 
aware of their condition. However in the presence of oxi-
dizing agents the reduced activity of the G6PD enzyme 
results in a dis-balanced redox equilibrium of the RBC 
and ultimate destruction of the cell, i.e. haemolysis [21]. 
Numerous compounds can induce haemolysis in G6PDd 
RBCs including 8-aminoquinoline based anti-malarial 
drugs [24].
Quantitative versus qualitative test formats
Diagnostic assays can be grouped into genotypic assays, 
sequencing methods as well as phenotypic test assays 
[7]. Genotypic assays and sequencing methods can pro-
vide a precise option for diagnosing G6PD mutations 
but require long and complicated test procedures, a 
well-equipped laboratory and highly trained staff [25, 
26]. Phenotypic tests can be grouped into qualitative, 
quantitative and cytochemical test assays. Phenotypic 
tests are based on the direct or indirect detection of 
NADPH + H+, formed as a result of G6PD activity [11].
Qualitative test formats indicate activity above a test’s 
inherent activity threshold level. While qualitative test 
formats are easier to perform and interpret compared 
to quantitative test methods and cytochemical tests, the 
reduction of a quantitative phenomenon (G6PD activ-
ity) to a binominal outcome is problematic. For techni-
cal reasons, current qualitative tests can only accurately 
diagnose G6PDd in people with G6PD activity below 
30–40  % normal activity [27–29]. While this accurately 
identifies all hemizygous G6PDd males and homozygous 
G6PDd females, females with heterozygous G6PD alleles 
are not accurately discriminated. G6PD normal and 
G6PDd red blood cell (RBC) populations can co-exist 
within a heterozygous female [7]. In these women, G6PD 
normal RBCs may mask G6PD deficient cell populations 
and can result in G6PD normal test results [27, 30–32]. 
Currently, the relationship between G6PD activity and 
degree of drug induced haemolysis is poorly understood 
and varies depending on the haemolytic potential of the 
applied drug [21].
A quantitative test assay will accommodate different 
threshold activities and within limits is able to identify 
heterozygous females as individuals with intermediate 
G6PD activity (as a result of G6PD normal and G6PD 
deficient cell populations). Most quantitative test assays 
to date require a good laboratory infrastructure and well-
trained staff. Handheld devices that do not rely on labora-
tory infrastructure and can provide results within several 
minutes are currently being introduced but require fur-
ther evaluation before treatment decisions can be based 
on these devices.
Only cytochemical assays can effectively distinguish 
between G6PD normal and G6PD deficient RBCs on a 
cellular level and can effectively identify heterozygous 
women with a high percentage of G6PDd red blood cells 
that are accordingly at risk for severe haemolysis [33]. 
There are flow cytometry-based assays that allow the 
measurement of G6PD activity in labelled RBCs [34]. 
The main drawbacks of this format are the complexity 
of the respective test assays and interpretation, the need 
for costly machinery and the long turn-around time that 
make these assays unsuitable for PoC testing.
Product options for point‑of‑care G6PD testing
For many years the Fluorescent Spot Test (FST) was the 
only available PoC for G6PD testing. The inherent limi-
tations of the FST include the requirement of basic lab 
facilities (refrigeration, a water bath, and UV light), the 
qualitative nature of the test and the need for significant 
upfront training of the test users [35]. In recent years 
novel technologies are changing the landscape [29, 36, 
37]. Included in these new technologies are three PoC 
devices (Table 2).
Two companies, Accessbio (New Jersey, USA) and 
Alere (Maine, USA), have developed different types of 
PoC diagnostics for G6PD deficiency that focus on rapid 
diagnosis, with limited need for technical training and 
infrastructure [28, 35]. Both companies have created 
qualitative RDTs. In addition to the RDT, CareStart has 
also produced a quantitative biosensor reader, which is 
currently under evaluation in several field sites.
The format of the qualitative, lateral flow RDT is simi-
lar to many malaria RDTs on the market. In contrast to 
the detection of Plasmodium antigens the G6PD RDT is 
based on the reduction of colourless nitro blue tetrazo-
lium dye to dark coloured formazan [38]. The appearance 
Page 4 of 12Ley et al. Malar J  (2015) 14:377 
Ta
bl
e 
2 
Su
m
m
ar
y 
sp
ec
ifi
ca
ti
on
s 
fo
r a
 s
ub
se
t o
f c
om
m
er
ci
al
ly
 a
va
ila
bl
e 
G
6P
D
 T
es
ts
So
ur
ce
s: 
Pr
ic
e 
in
fo
rm
at
io
n 
fo
r T
rin
ity
 G
-6
-P
D
H
 a
nd
 C
ar
eS
ta
rt
 G
6P
D
 R
D
T 
ba
se
d 
on
 v
on
 F
ric
ke
n 
et
 a
l. 
[5
3]
. C
ar
es
ta
rt
 G
6P
D
 R
D
T 
an
d 
Ca
re
st
ar
t B
io
se
ns
or
 c
on
fir
m
ed
 v
ia
 c
or
re
sp
on
de
nc
e 
w
ith
 A
cc
es
sb
io
. B
in
ax
N
ow
 p
ric
e 
is
 
fr
om
 c
or
re
sp
on
de
nc
e 
w
ith
 A
le
re
©
. T
rin
ity
 F
ST
 is
 a
n 
es
tim
at
ed
 p
ric
e 
pe
r u
se
 b
as
ed
 o
n 
re
ce
nt
 P
AT
H
 p
ur
ch
as
es
. E
nd
 p
ric
es
 to
 u
se
r w
ill
 v
ar
y 
w
id
el
y 
ba
se
d 
on
 lo
ca
l d
is
tr
ib
ut
or
 p
ric
in
g 
an
d 
in
 th
e 
ca
se
 o
f t
he
 a
ss
ay
 k
its
 (F
ST
 a
nd
 
sp
ec
tr
op
ho
to
m
et
ry
) i
nd
iv
id
ua
l l
ab
or
at
or
y 
sa
m
pl
e 
th
ro
ug
h 
pu
t a
nd
 w
or
kfl
ow
* 
Pr
ic
e 
va
rie
s 
ac
co
rd
in
g 
to
 n
um
be
r o
f s
am
pl
es
 ru
n/
co
nt
ro
l a
nd
 n
um
be
r o
f r
un
s 
pe
rf
or
m
ed
/s
am
pl
e
Te
st
 n
am
e
Re
so
ur
ce
 re
qu
ire
m
en
ts
 
(e
qu
ip
m
en
t, 
 
in
fr
as
tr
uc
tu
re
, e
tc
.).
Ki
t s
to
ra
ge
 te
m
p.
 
an
d 
co
m
pl
ex
it
y
N
um
be
r o
f  
st
ep
s 
fo
r s
am
pl
e 
pr
ep
To
ta
l t
im
e 
to
 re
su
lt
Th
ro
ug
h‑
pu
t 
ca
pa
ci
ty
W
or
ki
ng
  
te
m
p.
 ra
ng
es
Sp
ec
im
en
  
pr
es
er
va
tio
n 
 
in
di
ca
tio
ns
Pr
ic
e 
 
of
 p
ro
du
ct
Tr
in
ity
 G
‑6
‑P
D
H
 (k
in
et
ic
 
sp
ec
tr
op
ho
to
m
et
ry
)
El
ec
tr
ic
ity
, s
pe
ct
ro
ph
o‑
to
m
et
er
 w
ith
 te
m
p.
 c
on
‑
tr
ol
, p
ip
et
te
s, 
de
io
ni
ze
d 
w
at
er
, t
im
er
, w
at
er
 b
at
h 
(o
pt
io
na
l)
2°
–8
 °C
 a
nd
 h
ig
h
8
15
–2
5 
m
in
Lo
w
20
°–
39
 °C
1 
w
ee
k 
at
 2
°–
8 
°C
$1
0.
00
*
Tr
in
ity
 fl
uo
re
sc
en
t s
po
t 
te
st
 (F
ST
)
U
V 
lig
ht
 w
ith
 d
ar
k 
ro
om
 
or
 v
ie
w
in
g 
bo
x,
 p
ip
et
te
s, 
tim
er
2°
–8
 °C
 a
nd
 m
od
er
at
e
5
25
–3
0 
m
in
M
ed
iu
m
37
 °C
1 
w
ee
k 
at
 2
°–
8 
°C
~
$3
.0
0
Ca
re
St
ar
t G
6P
D
 s
cr
ee
n‑
in
g 
Te
st
Pi
pe
tt
es
, t
im
er
N
ot
 p
ro
vi
de
d 
an
d 
lo
w
3
5–
10
 m
in
M
ed
iu
m
–h
ig
h
N
ot
 s
pe
ci
fie
d
3 
da
ys
 a
t 2
°–
8 
°C
, o
r 
fro
ze
n
$1
.5
0
Bi
na
xN
O
W
 G
6P
D
 te
st
Pi
pe
tt
es
, t
im
er
15
°–
30
 °C
 a
nd
 lo
w
5
5–
7 
m
in
M
ed
iu
m
–h
ig
h
18
°–
25
 °C
N
ot
 s
pe
ci
fie
d
$2
0.
00
Ca
re
St
ar
t G
6P
D
 b
io
se
n‑
so
r t
es
t
O
nl
y 
ne
ed
le
 fo
r fi
ng
er
 s
tic
k
N
ot
 p
ro
vi
de
d 
an
d 
lo
w
1
4 
m
in
M
ed
iu
m
N
ot
 s
pe
ci
fie
d 
bu
t 
lik
el
y 
br
oa
d
N
ot
 s
pe
ci
fie
d
$5
00
 fo
r B
io
se
ns
or
, 
$2
.5
0 
pe
r t
es
t 
st
rip
Page 5 of 12Ley et al. Malar J  (2015) 14:377 
of a purple/blue coloration indicates a G6PD normal 
result. While the BinaxNOW G6PD test (Alere, USA), 
available since 2008, has good performance in controlled 
laboratory settings [27, 37] performance of this test in 
less controlled settings was less satisfactory [39]. In 2013, 
Accessbio (USA) released the CareStart G6PD test onto 
the market. Recent studies have indicated that the Car-
eStart G6PD test is non-inferior in the diagnosis of G6PD 
deficiency to the FST [28]. Furthermore, field studies in 
Cambodia have indicated that the CareStart G6PD RDT 
is capable of reliably detecting G6PD deficient individu-
als with enzyme activity levels <30 % of normal activity 
[29]. However, the current Carestart G6PD RDT does not 
include a control-line, a short-coming that affects result 
validity.
Biosensors, the second type of PoC device developed, 
are handheld devices that in conjunction with a dis-
posable strip provide a quantitative result. These tests 
directly measure G6PD activity from collected blood 
based on electro-chemical properties of the sample. In 
2015, AccessBio (USA) launched the CareStart Biosen-
sor, which at present, is the only product of this type on 
the market. The test is similar to a glucometer common 
in many developed country markets. The biosensor has 
a quantitative readout of G6PD activity and provides a 
number of advantages over a qualitative RDT, includ-
ing the possibility to design malaria treatment schemes 
based on the test readout, the ability to use readouts 
for drugs outside of 8-aminoquinolines and improved 
identification of heterozygous females with intermedi-
ate G6PD activity. The device has not been validated 
to date and is limited by the absence of an integrated 
haemoglobin Hb reader which is required for the esti-
mation of IU/g Hb. These are exciting and over-due 
new offerings in the G6PD testing product pipeline, 
but compared to malaria or HIV RDTs, the pipeline 
remains very thin.
Favorable environments for different test options
When G6PD status is unknown and G6PD testing is 
not available, the 2015 WHO treatment guidelines sug-
gest to base the decision to prescribe primaquine on an 
assessment of the risks and benefits of the treatment [8]. 
The ethical implications of primaquine therapy against 
malaria transmission and G6PD testing have been dis-
cussed recently and are beyond the scope of this report 
[40]. The risks of treatment are reduced under sev-
eral conditions such as a low prevalence of G6PDd, the 
absence of G6PD variants associated with severe hae-
molysis [41], and the absence of sub-populations at an 
increased risk of drug induced haemolysis. The benefits 
of radical cure are also likely to vary, depending on fac-
tors such as the patient profile, as well as the vivax strain 
and its associated probability and frequency of relapse. 
Finally, close follow-up of all patients receiving treat-
ment must be feasible and facilities to respond to severe 
haemolytic reactions must be available. Where the clini-
cal benefits of radical cure are assumed to outweigh the 
risk of haemolysis, the cost implications of treating rare 
haemolytic events should also be balanced against the 
cost savings from relapses avoided.
In reality, even where the risk/benefit ratio and eco-
nomic considerations would suggest that radical cure is 
advised without G6PD testing, clinicians often refrain 
from prescribing primaquine. There is a strong argument 
therefore to advocate G6PD testing more universally.
Routine testing using both the RDT and biosensor in 
point-of-care situations prior to vivax treatment has 
advantages but also risks. Based on strengths and weak-
nesses, three test and treat algorithms can be considered 
(Figs. 1, 2, 3).
Scenario 1
G6PD RDT (Fig.  1): The qualitative RDT provides a 
binary result that can be used at almost any level of the 
health system and requires little training. The RDT is 
well suited to discriminate homozygous and hemizygous 
G6PD deficient and G6PD normal males, but cannot 
identify heterozygous females, putting these women at 
increased risk for a potentially false normal G6PD result. 
All women testing G6PD normal by the RDT treated 
according to WHO treatment guidelines for radical cure 
in G6PD normal individuals [8] should be monitored 
for haemolysis during the first 7 days of treatment [42]; 
alternatively they can be treated with the 8 week 45 mg 
primaquine/week regimen as recommended for G6PD 
deficient individuals [8, 10]. RDT formats with a compa-
rable performance as the FST [28] have the potential to 
replace the latter in settings where the FST is currently 
in use due to superior operational characteristics, such 
as a faster turn-around time and no need for additional 
instrumentation or refrigeration.
Scenario 2
G6PD Biosensor (Fig. 2): The Biosensor can rapidly pro-
vide a quantitative result on G6PD activity, and poten-
tially allows identifying heterozygous women. All female 
patients with a Biosensor based G6PD normal results 
can undergo radical cure as recommended by the WHO 
[8] without further precautionary measures. Any patient 
identified as G6PD intermediate or deficient will require 
a prolonged course of treatment [8]. While the broad 
use of the Biosensor may appear ideal considering the 
increased treatment safety for female patients, it may 
come at a greater cost and the need additional techni-
cal training. In order for the Biosensor to be effective, 
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sound knowledge of G6PD threshold activities for dif-
ferent drugs and G6PD variants, as well as a universally 
applicable quantitative definition of G6PD deficiency 
may be needed; however, a hand held device can be pro-
grammed to provide a simple interpretation of the result 
and whether to provide treatment.
Fig. 1 G6PD qualitative RDT only
Fig. 2 G6PD quantitative biosensor only
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Scenario 3
Combined use of RDT and Biosensor (Fig. 3): The com-
bined product scenario creates the potential for a sys-
tem in which all male patients are tested with the RDT 
and the result is directly translated into a radical cure 
treatment scheme according to WHO guidelines [8]. All 
female patients are tested with the Biosensor to identify 
heterozygous females and treated with a prolonged pri-
maquine regimen [8].
Irrespective of the applied test format to determine 
G6PD status, prolonged primaquine courses are usually 
reserved for patients with mild to moderate G6PD defi-
ciency and only if appropriate monitoring and facilities 
are available to respond to severe haemolytic reactions 
[43].
Economics of testing for G6PD deficiency
The burden of P. vivax is difficult to determine for a vari-
ety of reasons. Firstly, cases often happen in areas where 
there are poor health care systems. Indirect costs of dis-
ease include lost productivity and transport to the health 
care facilities. Each relapse results in at least 3  days off 
work [1]. Time off work can contribute to poverty and 
malnutrition. In addition, recurrent disease makes peo-
ple more vulnerable to anemia and other diseases. It is 
also challenging to differentiate between primary epi-
sodes and relapses; in some areas it has been found that 
the majority of cases are relapses while in other areas 
primary infections are the lion’s share of the total burden 
[44, 45]. This confounds the understanding of the burden 
of disease as well as the potential impact of interventions 
to mitigate its effects.
G6PD testing can enable the wider use of primaquine 
to prevent relapses in areas where it is not used for fear 
of haemolysis. In areas that give out primaquine without 
knowledge of G6PD status, G6PD testing can enable the 
safer use of primaquine. Testing for G6PD deficiency and 
the selection of a specific test format prior to therapeutic 
decisions will have cost implications (Additional file 1). In 
addition to the aforementioned indirect costs, the direct 
costs will include the basic commodity costs, distribution 
costs, training costs, and human resource costs. G6PD 
testing will have direct and indirect effects on P. vivax 
malaria burden. By facilitating the use of primaquine the 
direct effects include (relapse) episodes of vivax averted 
and the costs associated with these. The indirect effects 
include the prevention of transmission, decreasing the 
incidence of new P. vivax infections. These are difficult to 
quantify due to our limited understanding of hypnozoites 
and the effect is likely to be highly heterogeneous.
Cost‑effectiveness models
Economic modelling can be used to look at the long-term 
costs and outcomes of G6PD screening and primaquine 
use. For P. vivax, these models might include decision 
trees to look at the outcome of a single episode, which 
Fig. 3 G6PD qualitative RDT and quantitative biosensor
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can be extended to Markov models to look at the impact 
of primaquine on recurrent episodes, or dynamic trans-
mission models to investigate the impact of primaquine 
on transmission. In these models, costs and outcomes are 
linked to information on disease progression to produce 
incremental cost-effectiveness ratios, such as the cost per 
DALY averted or the cost per infection averted.
These models can be used to look at whether G6PD 
testing is cost-effective for a given population where 
either P. vivax infections are not being treated with pri-
maquine or where primaquine is given without a G6PD 
test. In areas where primaquine is not currently being 
prescribed, a cost-effectiveness model will be important 
to demonstrate the long-term impact of primaquine on 
recurrences. Where primaquine is currently prescribed 
without G6PD testing, economic modelling could weigh 
the likelihood of haemolytic events against the burden of 
disease caused by recurrent vivax episodes. If haemolytic 
events are rare, it may be more economical to distribute 
primaquine without G6PD testing; however, medical staff 
must be comfortable implementing this policy choice. 
If health care providers have ethical concerns and are 
unwilling to take this risk, the economic justifications are 
not relevant.
Economic models could also be used to evaluate which 
of the aforementioned screening tests and strategies 
(Figs. 1, 2, 3) would be most cost-effective in a given set-
ting. The biosensor and RDT tests have different diag-
nostic accuracies and costs. Instead of simply looking 
at which test is least expensive, an economic model will 
synthesize the evidence concerning the epidemiology of 
vivax and the prevalence and variant of G6PD deficiency 
to determine which strategy will provide the most cost-
effective option in different settings. This evidence can 
enable the available malaria funding to be allocated more 
strategically.
Parameter values
Information needed for these models includes the prev-
alence of G6PDd in the population testing positive for 
vivax malaria, the probability of haemolysis or death 
when primaquine is given to a G6PD deficient individ-
ual, the probability of relapse if given or not given pri-
maquine, adherence to primaquine treatment, and the 
costs of all screening and treatment components. While 
the cost of a G6PD test is often set low by manufacturers, 
the cost to the healthcare provider is often inflated due to 
procurement and logistics. This will need to be investi-
gated by detailed costing research or through a sensitivity 
analysis in the model. Other costs that need better char-
acterization are those for clinical care of vivax cases, and 
those for the management of severe haemolytic events 
[46]. At this point, limited information exists on many of 
the parameters needed to populate an economic model; 
moreover, a number of these parameters are likely to vary 
by setting. Further research is needed to reduce uncer-
tainty and make these models informative.
In the future, economic modelling might capture wider 
implications of G6PD testing in other disease areas. 
G6PD deficiency is a common disorder and many other 
widely used drugs can cause haemolysis in G6PD defi-
cient individuals. More data would be needed to populate 
such a model but this could lead to further economic jus-
tification for the implementation of G6PD testing.
Health system integration: a review of four countries
A critical component to broader access and use of G6PD 
diagnostics is their integration into public health systems. 
Countries face a number of considerations when discuss-
ing implementation of a G6PD test including: P. vivax 
burden, elimination phase [47], income level, health 
budget, health system capacity to implement a new prod-
uct and degree of training required for relevant staff. 
Using these factors, four countries (Bangladesh, Cam-
bodia, Malaysia, and the Philippines; Tables 3, 4), across 
a variety of income, malaria burden and health capacity 
levels are reviewed here to assess the possibility and need 
to implement routine G6PD testing.
Malaysia has achieved a substantial reduction in malaria 
cases over the past several years, with 3850 cases reported 
Table 3 Background Country Information
Source: WHO World Malaria Report 2014 and APMEN
Bangladesh Cambodia Malaysia Philippines
PQ is used for radical treatment of P.vivax (in guidelines) Yes (2008) Yes (2015) Yes Yes (2007)
G6PD test is a requirement before treatment with PQ No Yes (2015) Yes Yes (2011)
Directly observed treatment with PQ is undertaken No No Yes Yes (2010)
# of confirmed malaria cases (all types) (year) 3864 (2013) 21,309 (2013) 3850 (2013) 6514 (2013)
% P. vivax 13 % 45 % 8 % 20 %
Treatment for vivax? Cq + PQ 0.25 mg/kg  
(14 days)
DHA‑PPQ + PQ 0.25 mg/kg  
(14 days)
CQ + PQ 0.5 mg/kg  
(14 days)
CQ + PQ 0.5 mg/kg  
(14 days)
Target Elimination Date 2030 2025 2020 2020
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in 2013, mostly concentrated in the Sabah and Sarawak 
regions of the country and the Central Highlands of 
Western Malaysia [47]. The country aims for elimination 
by 2017 and certification by 2020 [48]. Malaysia has had 
on-going malaria control and elimination strategies since 
the 1960s with original efforts at control beginning at the 
start of the 20th century. Currently, Malaysia uses inter-
nal budgeting to supply the resources necessary to combat 
malaria [48]. G6PD deficiency has been tackled through 
extensive use of the FST and G6PD deficiency tests are 
integrated into newborn screening programmes [49]. 
G6PD status is recorded and kept at the village and hos-
pital level so that appropriate treatment can be provided 
to patients. A single FST costs an estimated $0.28 per test 
and $140 for the FST specific equipment (national malaria 
control programme, personal communication) within the 
country. Malaysia maintains FST kits at all hospitals and 
health clinics. All malaria cases diagnosed in the country 
are admitted to a hospital. Malaysia provides in-patient 
care to P. vivax malaria patients and 14 days of 0.25 mg/
kg bw primaquine is provided to people with intermedi-
ate FST results (mild G6PD deficiency) compared to the 
0.5  mg/kg bw to G6PD normal patients. Concerns over 
the need for observation of patients for adverse haemo-
lytic events is limited and the exclusive use of a qualitative 
test format seems justified.
Routine G6PD testing in the Philippines started in 1998 
in the context of a comprehensive new born screening 
programme and became mandatory in 2004. While the 
Philippine government now finances 39  % of the anti-
malaria budget, with expectations to increase govern-
ment budget coverage to 57  % from 2015 to 2017, the 
bulk of the remaining funding comes from the Global 
Fund [50] The country is seeking to integrate routine 
G6PD testing into their national health insurance pro-
gramme and cover costs through internal resources (Fe 
Esperanza Espino, personal communication). Testing is 
conducted with FST at 5000 newborn screening centers 
across the country, with 20 confirmatory centers for all 
identified G6PD deficient individuals by spectrophotom-
etry. The Philippine records indicate that approximately 
2 % of the population is G6PD deficient [51]. The Philip-
pines is restructuring funding of G6PD testing, with the 
imminent cessation of Global Fund support overlapping 
with national efforts to ramp up their domestic capabili-
ties. Given the Philippines moderate domestic resources 
Table 4 Background information malaria screening and treatment
Questions Bangladesh Cambodia Malaysia Philippines
What are the current screening 
procedures for Pv?
Microscopy and RDT at health 
facilities and community level
Microscopy and 
RDT at health 
facilities, RDT 
at community‑
level
Microscopy Microscopy and RDTs. RDTs in rural health 
facilities by trained barangay health 
workers (BHWs). Microscopy in municipal 
health clinics and gov’t hospitals. Trained 
BHWs can also conduct microscopy
Active, passive, mass test or treat 
(MSAT), focused test and treat 
(FSAT)
Both active and passive case 
detection. Focused test and 
treat in pre‑elimination areas
Passive case 
detection, 
some active 
detection with 
research. No 
MSAT or FSAT
Active and 
passive case 
detection
Passive case detection, some active detec‑
tion
Is G6PD testing mandatory? Is 
it recommended prior to PQ 
administration?
Not mandatory Mandatory 
testing and 
recommended 
prior to PQ
Mandatory test‑
ing prior to PQ. 
All newborns 
tested at birth
Testing is recommended
If G6PD testing is not manda‑
tory, are their alternative 
procedures in place to assess 
and monitor risk of post‑
treatment haemolysis? Are 
patients monitored treatment 
adherence?
Patient is advised to report hae‑
molysis. Follow ups are done 
by NGO‑PR (BRAC supported 
consortium) at day 3, 7, and 14
No monitoring 
system in 
place
Patients are 
monitored
Patients are advised to report haemolysis. 
Treatment adherence is supposed to be 
monitored by BHW. No monitoring of 
haemolysis
Who performs the majority of 
screening activities?
Outreach Lab: Lab tech (NGO)
Community Clinic: community 
health care provider (CHCP)
Union sub‑centers: medical 
officer, health assistant (GoB)
Field Level: Health Assistant (GoB) 
or Shastho Kormi/Shastho 
Shebika (NGO)
Medical officer at the District, 
Upazila and Tertiary facility level
Lab tech, nurse, 
or community 
health worker
Medical lab 
techs and 
nurses
MDs at clinics and hospitals
Licensed midwives or BHW at rural health 
facilities
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and expected strain on budgets during the transition out 
of Global Fund programmes in coming years, the country 
may be able to optimize the use of both RDTs and biosen-
sors. Qualitative RDTs may be ideal for quick, PoC test-
ing by primary care providers and village health workers, 
while biosensors could provide more detailed data for 
potentially heterozygous females or customized therapy. 
While the FST has successfully been implemented in the 
country, the superior operational characteristics of the 
Carestart RDT render the latter a potential candidate to 
replace the FST in the long term.
Cambodia and Bangladesh are not testing G6PD sta-
tus on a routine basis [52]. In light of the haemolytic risk 
of primaquine Cambodia only recently recommended 
single dose primaquine treatment in P. falciparum cases 
without G6PD testing [29], while Bangladesh provides 
primaquine for radical cure on a regular basis. In the 
absence of alternative drugs to primaquine for hypno-
zoitocidal treatment Cambodia will eventually need to 
include the drug in its treatment schedules in order to 
pursue malaria elimination from the country [6]. Cam-
bodia will only make primaquine radical cure for vivax 
available when it can test reliably for G6PDd.
Following current WHO guidelines [8] the practice of 
providing radical cure without routine G6PD testing calls 
for a comprehensive risk—benefit analysis within Bangla-
desh, surveys to assess the local prevalence of G6PDd are 
under way in parts of the country [51].
Discussion and conclusion
The potential risks of 8-aminoquinoline therapy in the 
small subpopulation of G6PD deficient vivax patients 
have hindered the appropriate treatment of the large 
majority of vivax patients. The availability of affordable 
PoC tests for G6PDd is essential to detect at-risk patients 
and to optimize the management of vivax malaria. New 
G6PD tests are becoming available which may be able 
to help calibrate the most appropriate 8-aminoquino-
line regimen for patients with vivax malaria. A quantita-
tive, easy to use and handheld test device that can also 
provide a haemoglobin concentration would add great 
value. Current qualitative RDT formats can reliably clas-
sify hemizygous males and homozygous females, but 
may fail to correctly diagnose heterozygous females with 
intermediate G6PD activity. Nevertheless the format of a 
qualitative test is appealing, due to the similarity of the 
product to malaria RDTs, its ease of use and a perfor-
mance comparable to the most routinely used test, the 
FST.
The roll out of G6PD testing will have implications 
in terms of costs. It will be important to understand 
these costs with different product concepts having dif-
ferent cost structures which will be defined by applied 
treatment algorithms, local P. vivax epidemiology and the 
local health system. Much of the data needed for these 
analyses are not yet available. Future research should 
include data collection appropriate for use in cost-effec-
tiveness studies, which will be useful to inform different 
implementation modalities.
With increasing availability of PoC tests for G6PDd 
comes the potential to extend the coverage of radical 
cure and advance towards elimination of vivax malaria. 
To this end it is essential to strengthen the knowledge 
on how best to introduce and integrate G6PD tests into 
clinical practice based on cost and operational feasibility 
evidence.
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